Shots: AbCellera to receive technology access fee, milestones and royalties on the development and commercialization of pre-cliniocal candidates & will develop Abs for Denali’s eight targets for neurological disorders On 12 Jun,2018 Denali therapeutics collaborated with AbCellera for its single-cell technology to develop hundreds of mAbs for neurodegenerative diseases AbCellera’s single-cell screening technology is a […]Read More
Shots: Denali to get $125M upfront plus milestones payments that can exceed $1B and will also receive royalties for DNL747 (ex-US & China) & DNL758 (WW). The profit/loss sharing will be divided equally and this partnership also includes pre-clinical RIPK1 inhibitor candidate Sanofi will fund DNL747 (P-Ib & P-II) & DNL747 in MS (multiple sclerosis), […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
